PMID- 37991535
OWN - NLM
STAT- Publisher
LR  - 20231122
IS  - 1433-8491 (Electronic)
IS  - 0940-1334 (Linking)
DP  - 2023 Nov 22
TI  - Effect modification of tumor necrosis factor-alpha on the kynurenine and serotonin 
      pathways in major depressive disorder on type 2 diabetes mellitus.
LID - 10.1007/s00406-023-01713-8 [doi]
AB  - Major depressive disorder (MDD) is strongly associated with type 2 diabetes 
      mellitus (T2DM). The kynurenine and serotonin pathways, as well as chronic 
      low-grade inflammation, are being considered potential links between them. MDD 
      associated with T2DM is less responsive to treatment than that without T2DM; 
      however, the underlying mechanism remains unknown. We aimed to investigate the 
      effects of inflammatory cytokines on the kynurenine and serotonin pathways in 
      patients with comorbid MDD and T2DM and those with only MDD. We recruited 13 
      patients with comorbid MDD and T2DM and 27 patients with only MDD. We measured 
      interleukin-6 and tumor necrosis factor-alpha (TNF-alpha) levels as inflammatory 
      cytokines and metabolites of the kynurenine pathway and examined the relationship 
      between the two. TNF-alpha levels were significantly higher in patients with comorbid 
      MDD and T2DM than in those with only MDD in univariate (p = 0.044) and 
      multivariate (adjusted p = 0.036) analyses. TNF-alpha showed a statistically 
      significant effect modification (interaction) with quinolinic acid/tryptophan and 
      serotonin in patients from both groups (beta = 1.029, adjusted p < 0.001; 
      beta =  - 1.444, adjusted p = 0.047, respectively). Limitations attributed to the 
      study design and number of samples may be present. All patients were Japanese 
      with mild to moderate MDD; therefore, the generalizability of our findings may be 
      limited. MDD with T2DM has more inflammatory depression components and 
      activations of the kynurenine pathway by inflammatory cytokines than MDD without 
      T2DM. Hence, administering antidepressants and anti-inflammatory drugs in 
      combination may be more effective in patients with comorbid MDD and T2DM.
CI  - (c) 2023. The Author(s).
FAU - Okamoto, Naomichi
AU  - Okamoto N
AUID- ORCID: 0000-0003-2791-8113
AD  - Department of Psychiatry, University of Occupational and Environmental Health, 
      807-8555, Kitakyushu, Fukuoka, 8078555, Japan. nokamoto@med.uoeh-u.ac.jp.
FAU - Hoshikawa, Takashi
AU  - Hoshikawa T
AD  - Department of Psychiatry, University of Occupational and Environmental Health, 
      807-8555, Kitakyushu, Fukuoka, 8078555, Japan.
FAU - Honma, Yuichi
AU  - Honma Y
AD  - Third Department of Internal Medicine, University of Occupational and 
      Environmental Health, Fukuoka, Japan.
FAU - Chibaatar, Enkhmurun
AU  - Chibaatar E
AD  - Department of Psychiatry, University of Occupational and Environmental Health, 
      807-8555, Kitakyushu, Fukuoka, 8078555, Japan.
FAU - Ikenouchi, Atsuko
AU  - Ikenouchi A
AD  - Department of Psychiatry, University of Occupational and Environmental Health, 
      807-8555, Kitakyushu, Fukuoka, 8078555, Japan.
AD  - Medical Center for Dementia, University Hospital, University of Occupational and 
      Environmental Health, Fukuoka, Japan.
FAU - Harada, Masaru
AU  - Harada M
AD  - Third Department of Internal Medicine, University of Occupational and 
      Environmental Health, Fukuoka, Japan.
FAU - Yoshimura, Reiji
AU  - Yoshimura R
AD  - Department of Psychiatry, University of Occupational and Environmental Health, 
      807-8555, Kitakyushu, Fukuoka, 8078555, Japan.
LA  - eng
GR  - 18K07576/Ministry of Health, Labour and Welfare/
PT  - Journal Article
DEP - 20231122
PL  - Germany
TA  - Eur Arch Psychiatry Clin Neurosci
JT  - European archives of psychiatry and clinical neuroscience
JID - 9103030
SB  - IM
OTO - NOTNLM
OT  - Inflammatory cytokine
OT  - Kynurenine pathway
OT  - Major depressive disorder
OT  - Tryptophan metabolism
OT  - Tumor necrosis factor-alpha
OT  - Type 2 diabetes mellitus
EDAT- 2023/11/22 12:43
MHDA- 2023/11/22 12:43
CRDT- 2023/11/22 11:05
PHST- 2023/08/17 00:00 [received]
PHST- 2023/10/29 00:00 [accepted]
PHST- 2023/11/22 12:43 [medline]
PHST- 2023/11/22 12:43 [pubmed]
PHST- 2023/11/22 11:05 [entrez]
AID - 10.1007/s00406-023-01713-8 [pii]
AID - 10.1007/s00406-023-01713-8 [doi]
PST - aheadofprint
SO  - Eur Arch Psychiatry Clin Neurosci. 2023 Nov 22. doi: 10.1007/s00406-023-01713-8.